Focused On-demand Library for Aspartyl aminopeptidase

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9ULA0

UPID:
DNPEP_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9ULA0; Q9BW44; Q9NUV5; Q9NV55

BACKGROUND:
The enzyme Aspartyl aminopeptidase plays a pivotal role in the degradation of intracellular proteins by specifically cleaving acidic amino acids at the N-terminus. This activity is vital for the regulation of protein turnover and cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Aspartyl aminopeptidase offers a promising avenue for the development of novel therapeutic approaches. Its critical role in protein metabolism highlights its potential as a target in diseases related to protein dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8778 of 8789